Astrazeneca Pharma India Ltd vs Godavari Drugs Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8233 as of 05 May 15:30 . The P/E Ratio of Astrazeneca Pharma India Ltd changed from 80.7 on March 2021 to 185.9 on March 2025 . This represents a CAGR of 18.16% over 5 yearsThe P/E Ratio of Godavari Drugs Ltd changed from 8.4 on March 2021 to 15 on March 2025 . This represents a CAGR of 12.30% over 5 years The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 7525 crore on March 2021 to ₹ 21515 crore on March 2025 . This represents a CAGR of 23.38% over 5 yearsThe Market Cap of Godavari Drugs Ltd changed from ₹ 34.45 crore on March 2021 to ₹ 65.86 crore on March 2025 . This represents a CAGR of 13.84% over 5 years The revenue of Astrazeneca Pharma India Ltd for the Jun '25 is ₹ 537.55 crore as compare to the Dec '25 revenue of ₹ 618.18 crore. This represent the decline of -13.04% The revenue of Godavari Drugs Ltd for the Jun '25 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 22.45 crore. This represent the decline of -100% The ebitda of Astrazeneca Pharma India Ltd for the Jun '25 is ₹ 91.99 crore as compare to the Dec '25 ebitda of ₹ 51.44 crore. This represent the growth of 78.83% The ebitda of Godavari Drugs Ltd for the Jun '25 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 2.75 crore. This represent the decline of -100% The net profit of Astrazeneca Pharma India Ltd changed from ₹ -11.79 crore to ₹ 55.83 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Godavari Drugs Ltd changed from ₹ 1.63 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of -100.00% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of Godavari Drugs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Godavari Drugs Ltd

Godavari Drugs Limited is engaged in the business of manufacture of Active Pharmaceutical Ingredients (API) and drug intermediates, through its manufacturing facility at Nanded, Maharashtra, India..
Sulphamethoxazole (SMX), the main product of the company, is a widely used anti-bacterial drug enjoying good export demand. The Company incorporated in December, 1987, has multiple production blocks for API's, drug intermediates and fine chemicals. The company has expanded its SMX capacity from 540 tpa to 720 tpa, integrating backward into the manufacture of drug intermediates, sulphamethoxide (cap.: 450 tpa) and diethyl oxalate, DEO (cap.: 750 tpa), and diversifying into the manufacture of trimetroprim, TMP (cap.: 144 tpa). The diversification into TMP is beneficial as SMX and TMP are used in combination to treat a wide variety of infections.

FAQs for the comparison of Astrazeneca Pharma India Ltd and Godavari Drugs Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Godavari Drugs Ltd?

Market cap of Astrazeneca Pharma India Ltd is 20,583 Cr while Market cap of Godavari Drugs Ltd is 126 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Godavari Drugs Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Godavari Drugs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Godavari Drugs Ltd?

As of May 5, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8233.5. On the other hand, Godavari Drugs Ltd stock price is INR ₹124.95.

How do dividend payouts of Astrazeneca Pharma India Ltd and Godavari Drugs Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Godavari Drugs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.